May 9, 2023 7:40am

Earnings: AxoGen (AXGN), bluebird bio (BLUE), uniQure NV (QURE), Voyager Therapeutics (VYGR) and Agenus (AGEN)

Pre-open indications: 1 Positive and 1 Negative indications

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today, not tomorrow or yesterday.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday

 

Dow futures are DOWN -0.39% or (-130 points), S&P futures are DOWN -0.38% or (-15 point) and NASDAQ futures are DOWN -0.43 or (-56 points) early in the pre-open – so far

Stock futures were floating down on Tuesday,

European markets were lower,

Asia Pacific markets were also pressured down.

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes were mixed on Monday as the Dow closed DOWN -55.69 points (-0.17%), the S&P closed UP +1.87 points (+0.05%) while the Nasdaq closed UP +21.50 points (+0.18%)

On target quote, “If we look across markets today, the price action is relatively muted. There’s somewhat of a sigh of relief that the report wasn’t worse than expected.”< Charlie Ripley, senior investment strategist at Allianz Investment Management>

Economic Data Docket: April’s consumer price index report slated for Wednesday and the producer price index on Thursday

 

Monday’s (5/8) … RegMed Investors’ (RMi) closing bell: “Along came the cell/gene therapy sector falling back after last week’s rally.” … https://www.regmedinvestors.com/articles/12949

 

Ebb and flow:

Q2/23 – May – 2 negative and 4 positive closes

·         April ended - 1 holiday, 8 positive close and 11 negative closes

Q1/23 –

·         March – ended with 10 positive and 13 negative closes

·         February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

·         January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive Indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Sage Therapeutics (SAGE) closed up +$2.41 with a positive +$0.53 or +1.03% aftermarket indication

 

Negative Indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Chinook Therapeutics (KDNY) closed up +$0.85 with a negative -$0.11 or -0.52% aftermarket indication

 

The BOTTOM LINE: I try to keep it simple and short!

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

As I stated Friday, I wouldn’t buy into ANY rally, I’d be selling and I have been RIGHT.

This week’s special, sector earnings continue rolling out … NOT a single NET INCOME to date yet, 14 net losses.

The cell and gene therapy sector could experience the “flight of Icarus” …  since “our” universe have oscillated between gains and losses since the first of 2023!

Reiterating, “More frequently right than consequentially wrong … “The rubber is hitting the road, so those companies have to do quite well to justify it.” What is the “it” – as LPS (loss-per-share) numbers facilitate downslides.”

Investors should STILL be hesitant to add to positions re concerns of electronic trading i.e., algorithms seem to be the only ones leading any upside – go with flow.

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!

At ANY time, this week, be ready to take partial profits and exit losers.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.